Standard BioTools Inc. Standard and Extended Product Warranty Accrual, Decrease for Payments
Standard BioTools Inc. (LAB) reported Standard and Extended Product Warranty Accrual, Decrease for Payments of $875.00 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Notes › Product Warranties Disclosures
us-gaap:ProductWarrantyAccrualPayments · last filed 2022-11-09
- Standard BioTools Inc. standard and extended product warranty accrual, decrease for payments for the quarter ending 2022-09-30 was $285.00K, a 49.21% increase year-over-year.
- Standard BioTools Inc. standard and extended product warranty accrual, decrease for payments for the quarter ending 2022-06-30 was $326.00K, a 13.99% increase year-over-year.
- Standard BioTools Inc. standard and extended product warranty accrual, decrease for payments for the quarter ending 2022-03-31 was $264.00K, a 11.86% increase year-over-year.
- Standard BioTools Inc. standard and extended product warranty accrual, decrease for payments for the quarter ending 2021-12-31 was $198.00K, a 46.20% decline year-over-year.
- Standard BioTools Inc. standard and extended product warranty accrual, decrease for payments for fiscal 2021 was $911.00K, a 20.66% increase from fiscal 2020.
- Standard BioTools Inc. standard and extended product warranty accrual, decrease for payments for fiscal 2020 was $755.00K, a 12.11% decline from fiscal 2019.
- Standard BioTools Inc. standard and extended product warranty accrual, decrease for payments for fiscal 2019 was $859.00K, a 39.03% decline from fiscal 2018.
- Standard BioTools Inc. standard and extended product warranty accrual, decrease for payments for fiscal 2018 was $1.41M, a 38.27% increase from fiscal 2017.
| Period end | Standard and Extended Product Warranty Accrual, Decrease for Payments 3 month | Standard and Extended Product Warranty Accrual, Decrease for Payments 6 month | Standard and Extended Product Warranty Accrual, Decrease for Payments 9 month | Standard and Extended Product Warranty Accrual, Decrease for Payments 12 month |
|---|---|---|---|---|
| 2022-09-30 | $285.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $611.00K derived: sum of 2 quarters · filed 2022-11-09 | $875.00K 10-Q · filed 2022-11-09 | $1.07M derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | $326.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $590.00K 10-Q · filed 2022-08-09 | $788.00K derived: sum of 3 quarters · filed 2022-08-09 | $979.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-03-31 | $264.00K 10-Q · filed 2022-05-09 | $462.00K derived: sum of 2 quarters · filed 2022-05-09 | $653.00K derived: sum of 3 quarters · filed 2022-11-09 | $939.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-12-31 | $198.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $389.00K derived: sum of 2 quarters · filed 2022-11-09 | $675.00K derived: sum of 3 quarters · filed 2022-11-09 | $911.00K 10-K · filed 2022-03-08 |
| 2021-09-30 | $191.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $477.00K derived: sum of 2 quarters · filed 2022-11-09 | $713.00K 10-Q · filed 2022-11-09 | $1.08M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $286.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $522.00K 10-Q · filed 2022-08-09 | $890.00K derived: sum of 3 quarters · filed 2022-08-09 | $1.00M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $236.00K 10-Q · filed 2022-05-09 | $604.00K derived: sum of 2 quarters · filed 2022-05-09 | $714.00K derived: sum of 3 quarters · filed 2022-05-09 | $829.00K derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $368.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $478.00K derived: sum of 2 quarters · filed 2022-03-08 | $593.00K derived: sum of 3 quarters · filed 2022-03-08 | $755.00K 10-K · filed 2022-03-08 |
| 2020-09-30 | $110.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $225.00K derived: sum of 2 quarters · filed 2021-11-09 | $387.00K 10-Q · filed 2021-11-09 | $578.00K derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $115.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $277.00K 10-Q · filed 2021-08-06 | $468.00K derived: sum of 3 quarters · filed 2021-08-06 | $707.00K derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | $162.00K 10-Q · filed 2021-05-07 | $353.00K derived: sum of 2 quarters · filed 2021-05-07 | $592.00K derived: sum of 3 quarters · filed 2021-05-07 | $802.00K derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $191.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $430.00K derived: sum of 2 quarters · filed 2021-02-25 | $640.00K derived: sum of 3 quarters · filed 2021-02-25 | $859.00K 10-K · filed 2021-02-25 |
| 2019-09-30 | $239.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $449.00K derived: sum of 2 quarters · filed 2020-11-09 | $668.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $210.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $429.00K 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | $219.00K 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $1.41M 10-K · filed 2020-02-27 | |||
| 2017-12-31 | $1.02M 10-K · filed 2019-03-18 | |||
| 2016-12-31 | $938.00K 10-K · filed 2018-03-08 | |||
| 2015-12-31 | $774.00K 10-K · filed 2017-03-03 | |||
| 2014-12-31 | $1.25M 10-K · filed 2016-02-29 | |||
| 2013-12-31 | $561.00K 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |